Metabolic Syndrome — Symptoms, Causes & Treatment | MyMedicPlus

Metabolic syndrome is a cluster of cardiometabolic risk factors that occur together, dramatically increasing the risk of type 2 diabetes mellitus, cardiovascular disease (coronary artery disease, myocardial infarction, stroke), and non-alcoholic fatty liver disease. Diagnosis requires 3 of 5 criteria defined by the National Cholesterol Education Program Adult Treatment Panel III (ATP III): abdominal obesity (waist circumference above 102 cm in men, 88 cm in women — lower thresholds in Asian populations: 90 cm and 80 cm respectively), elevated triglycerides (above 1.7 mmol/L), reduced HDL cholesterol (below 1.0 mmol/L in men, 1.3 mmol/L in women), elevated blood pressure (above 130/85 mmHg), and elevated fasting plasma glucose (above 5.6 mmol/L). Metabolic syndrome affects approximately 25–35% of adults globally and its prevalence is rising in parallel with the global obesity epidemic. It represents a major public health concern — each additional component multiplies cardiovascular risk. The condition is often entirely asymptomatic, making routine screening critical. Insulin resistance is the central pathophysiological mechanism linking all five components and is the target of lifestyle and pharmacological treatment.

Insulin resistance is the central and unifying pathophysiological mechanism of metabolic syndrome — peripheral tissues (skeletal muscle, adipose tissue, and liver) fail to respond normally to insulin signalling, leading to compensatory hyperinsulinaemia and progressive glucose intolerance. Visceral adiposity (excess intra-abdominal fat, particularly omental fat) drives insulin resistance through release of pro-inflammatory adipokines (TNF-alpha, IL-6, resistin — elevated) and reduced adiponectin secretion. Key risk factors: central obesity — the most important modifiable risk factor; physical inactivity (independent risk factor, separate from obesity effects); high-calorie, high-glycaemic-index, and high-saturated-fat diet; genetic predisposition (family history of T2DM or cardiovascular disease); ethnicity (South Asians, Hispanic Americans, and East Asians develop insulin resistance at lower BMI than Caucasians, requiring lower diagnostic waist thresholds); polycystic ovarian syndrome (PCOS) in women; obstructive sleep apnoea (causes insulin resistance through intermittent hypoxia and sympathetic activation); ageing (insulin sensitivity declines with age independently of adiposity); and medications including atypical antipsychotics (olanzapine, clozapine, quetiapine — cause significant metabolic side effects), long-term corticosteroids, and certain antihypertensives (thiazides, beta-blockers — can impair glucose metabolism).

Metabolic syndrome itself is largely asymptomatic in the short term — most people are unaware they have it until identified through routine screening or when complications arise. Abdominal obesity (central, apple-shaped distribution — excess fat at the waist rather than hips — measured at umbilicus level) is the most visible external sign and is readily identifiable on clinical examination. Hypertension is typically asymptomatic but can cause occipital headaches (worst on waking), visual disturbance, or epistaxis in severe cases. Hyperglycaemia, if progressing towards or at the type 2 diabetes threshold, causes: polydipsia (excessive thirst), polyuria (frequent urination, particularly nocturia), fatigue, and blurred vision. Acanthosis nigricans — velvety, hyperpigmented skin changes in the axillae, neck, groin, and inframammary areas — is a clinically visible cutaneous marker of significant insulin resistance and should prompt investigation. Dyslipidaemia itself causes no direct symptoms, but xanthelasma (cholesterol deposits around the eyelids) or corneal arcus in those under 50 may indicate significant lipid abnormalities. Non-alcoholic fatty liver disease (NAFLD), affecting approximately 70% of metabolic syndrome patients, is usually asymptomatic but may cause mild right upper quadrant discomfort or hepatomegaly. The syndrome is most commonly discovered incidentally during routine cardiovascular risk assessment or screening blood tests.

Five parameters must be measured for formal diagnosis — three must meet criteria: waist circumference (measured at the level of the umbilicus or midway between the lowest rib and iliac crest, using a non-elastic tape at end-expiration), blood pressure (resting, measured after 5 minutes sitting — use the higher of two readings), and a fasting blood sample (minimum 8 hours fast) for fasting plasma glucose, fasting serum triglycerides, and HDL cholesterol. ATP III diagnostic criteria: waist circumference above 102 cm (men) or above 88 cm (women) — using IDF criteria, lower thresholds apply for Asian populations (90/80 cm); triglycerides above 1.7 mmol/L or on fibrate or niacin therapy; HDL cholesterol below 1.0 mmol/L (men) or below 1.3 mmol/L (women) or on HDL-raising therapy; blood pressure above 130/85 mmHg or on antihypertensive therapy; and fasting plasma glucose above 5.6 mmol/L or on antidiabetic medication. Additional investigations: HbA1c (to classify glucose status as normal, impaired, or diabetic); HOMA-IR score (fasting insulin × fasting glucose / 22.5 — above 2.5 indicates significant insulin resistance); uric acid (commonly elevated in metabolic syndrome — gout association); LFTs and liver ultrasound (NAFLD assessment — approximately 70% prevalence in metabolic syndrome); renal function and urine ACR (early nephropathy detection); and ECG (left ventricular hypertrophy from hypertension).

Intensive lifestyle modification is the cornerstone and most effective first-line treatment, targeting the underlying insulin resistance and adiposity. Weight reduction: a 5–10% reduction in body weight improves all five metabolic parameters and reverses the full syndrome in up to 60% of patients — even without achieving target BMI. Aerobic exercise (150–300 minutes per week of moderate-intensity activity — walking at 5 km/h, cycling, swimming) independently improves insulin sensitivity, reduces triglycerides, raises HDL, and lowers blood pressure. Resistance training (2–3 sessions per week) increases skeletal muscle mass and insulin-mediated glucose uptake. Dietary approaches: Mediterranean diet (high in vegetables, whole grains, legumes, fish, olive oil, nuts; low in refined carbohydrates and saturated fat) — the most evidence-based dietary pattern; low-carbohydrate diets effectively reduce triglycerides and improve glycaemic control; caloric restriction achieving a 500–750 kcal/day deficit is the practical dietary goal. Pharmacotherapy targets individual components: statins (atorvastatin 20–80 mg, rosuvastatin 10–40 mg) for LDL elevation and cardiovascular risk reduction; ACE inhibitors (ramipril 5–10 mg) or ARBs (losartan, candesartan) for hypertension — also modestly improve insulin sensitivity; metformin 500–2000 mg/day for impaired fasting glucose or impaired glucose tolerance (reduces T2DM progression by 31% in the Diabetes Prevention Program); fenofibrate for severe hypertriglyceridaemia (above 5–10 mmol/L); GLP-1 receptor agonists (semaglutide, liraglutide) achieve substantial weight loss and cardiovascular benefit in metabolic syndrome with T2DM or obesity; bariatric surgery (Roux-en-Y or sleeve gastrectomy) for BMI above 35 with metabolic comorbidities dramatically reverses metabolic syndrome in the majority.

Metabolic syndrome increases type 2 diabetes risk 5-fold and cardiovascular disease (coronary artery disease, myocardial infarction, stroke) risk approximately 2-fold compared to individuals without the syndrome. Non-alcoholic fatty liver disease (NAFLD) is present in approximately 70% of patients with metabolic syndrome; in a proportion (10–20%), NAFLD progresses to NASH (non-alcoholic steatohepatitis) with active liver inflammation, and subsequently to cirrhosis and hepatocellular carcinoma — an increasingly important cause of liver-related mortality. Chronic kidney disease develops from combined hypertension- and hyperglycaemia-mediated renal damage. Gout (from elevated uric acid, which is independently associated with insulin resistance) is a comorbidity. Obstructive sleep apnoea, highly prevalent (40–60%) in metabolic syndrome, further worsens insulin resistance and cardiovascular risk through nocturnal hypoxaemia and sympathetic activation. Atherosclerosis progresses silently over years, eventually causing myocardial infarction, stroke, peripheral arterial disease, and premature death. Polycystic ovarian syndrome in women is both a driver and consequence of insulin resistance in metabolic syndrome. The risk multiplies with each additional component present beyond the diagnostic threshold.

Preventing metabolic syndrome centres on addressing its key modifiable risk factors. Maintain a healthy body weight — particularly avoiding central (abdominal) adiposity — through a balanced, Mediterranean-style diet low in refined carbohydrates, processed foods, added sugars, and saturated fat. Engage in at least 150–300 minutes of moderate aerobic exercise per week, plus resistance training 2–3 times weekly — the most effective single intervention for preventing insulin resistance. Avoid smoking (accelerates atherosclerosis and worsens insulin resistance) and limit alcohol consumption to below 14 units per week. Annual cardiovascular risk screening (blood pressure, fasting glucose, fasting lipid profile) is recommended for all adults over 40 and for high-risk individuals (family history of T2DM or CVD, South Asian or Black ethnicity, overweight, or PCOS) from age 30. Even modest lifestyle improvements — a 5% weight reduction and 30 minutes of daily walking — are highly effective at preventing progression from metabolic syndrome to type 2 diabetes and cardiovascular disease. Metformin can be considered for diabetes primary prevention in individuals with impaired fasting glucose who do not achieve lifestyle targets. GLP-1 receptor agonists (semaglutide) are now an important tool for high-risk individuals with obesity.

See your GP for a cardiovascular risk assessment if you have a waist circumference above 102 cm (men) or above 88 cm (women), are overweight with a family history of type 2 diabetes or heart disease, or have been told you have high blood pressure, raised blood sugar, or abnormal cholesterol. Metabolic syndrome is largely asymptomatic — routine checks are the key to detection. Many people are unaware they have metabolic syndrome until they develop type 2 diabetes or experience a cardiovascular event. Seek urgent assessment for: chest pain or breathlessness (possible angina or heart failure); new-onset polyuria and polydipsia (symptoms of undiagnosed type 2 diabetes); transient weakness, slurred speech, or facial droop (TIA — transient ischaemic attack — requires same-day emergency assessment). The combination of abdominal obesity, raised blood pressure, impaired fasting glucose, and dyslipidaemia together dramatically multiplies cardiovascular and diabetes risk — early intervention through lifestyle change and medication (statins, antihypertensives, metformin) is highly effective.